Search
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. … It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 4'-N-benzoylstaurosporineEstradiol benzoate
go.drugbank.com/drugs/DB13953ApprovedVet approvedWithdrawnEstradiol Benzoate is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. … As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Categories: Hormonal Contraceptives for Systemic UseOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard … Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.
Kojic acid
go.drugbank.com/drugs/DB01759ApprovedMixtures: Skin White Pro Strength Kojic and Hyaluronic Skin Lightening SerumCategories: Compounds used in a research, industrial, or household settingPexidartinib
go.drugbank.com/drugs/DB12978ApprovedInvestigational[L7901] While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime … Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexFerric chloride
go.drugbank.com/drugs/DB15536ApprovedMixtures: ADDAMEL N FOR INFUSION, Addaven Concentrate for Solution for InfusionOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Silver
go.drugbank.com/drugs/DB12965ApprovedInvestigationalSilver (Ag) is a chemical element that belongs in the family of transition metals in the periodic table. It has a high electrical conductivity, thermal conductivity, and reflectivity. … Having critical roles in various applications inducing chemical and industrial fields, silver compounds have also been used in the field of medicine for centuries due to their broad-spectrum biological
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
Categories: Pro-OpiomelanocortinPlazomicin
go.drugbank.com/drugs/DB12615ApprovedOn June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. … Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604].
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Antibacterials for Systemic Use